Skip to main content
. 2024 Feb 29;18(10):7618–7632. doi: 10.1021/acsnano.4c00550

Figure 6.

Figure 6

Impact of AnCHNPs on immune responses, tested in vivo in B16F10-OVA-tumor-bearing C57BL/6 mice. (a) Experimental scheme. On Day 0, the animals received radiation (10 Gy) applied to tumors, followed by i.t. administration of AnCHNPs (200 μg/kg) (RT + AnCHNPs; n = 10). CaCl2 plus RT (RT + CaCl2) and PBS plus RT (RT + PBS) were tested in control groups (n = 10). Half of the animals from each group were euthanized on Day 3, while the rest were euthanized on Day 7. Tumor, TDLNs, and spleen tissues were harvested for flow cytometry. Serum samples were collected for ELISA analysis. (b) Overall DC population in tumors on Day 3 and 7. (c) Populations of CD86+CD80+, CD40+, MHC-II+, and MHC-II+SIINFEKL-H-2Kb+ DCs in tumors and TDLNs on Day 3 and Day 7. (d) T lymphocyte populations, including CTLs (CD45+CD3+CD8+), effector CTLs (IFN-γ+CD45+CD3+CD8+), and Tregs (CD45+CD3+CD4+Foxp3+), in both the tumor and spleen on Day 3 and Day 7. CTL/Treg ratios were also calculated. (e) Serum cytokine levels, including IL-12, IFN-γ, IL-10, IL-1β, IL-6, and TNF-α, on Day 3 and Day 7. Data are presented as the mean ± s.d. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.